Stockscreener 앱 받기
1.75
8.02%
0.13
시간 외 거래:
1.82
0.07
+4.00%
전일 마감가:
$1.62
열려 있는:
$1.63
하루 거래량:
691.85K
Relative Volume:
0.49
시가총액:
$67.31M
수익:
$210.70K
순이익/손실:
$-21.37M
주가수익비율:
-1.5909
EPS:
-1.1
순현금흐름:
$-21.10M
1주 성능:
-2.78%
1개월 성능:
-31.37%
6개월 성능:
+13.27%
1년 성능:
-33.71%
1일 변동 폭
$1.63
$1.82
1주일 범위
$1.61
$1.9492
52주 변동 폭
$1.41
$4.34
게인 테라퓨틱스 Stock (GANX) Company Profile
명칭
Gain Therapeutics Inc
전화
(301) 500-1556
주소
4800 HAMPDEN LANE, BETHESDA
Compare GANX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GANX
Gain Therapeutics Inc
|
1.75 | 62.31M | 210.70K | -21.37M | -21.10M | -1.10 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
게인 테라퓨틱스 Stock (GANX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-03-07 | 개시 | Scotiabank | Sector Outperform |
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-08-14 | 재개 | Oppenheimer | Outperform |
| 2021-04-12 | 개시 | BTIG Research | Buy |
| 2021-04-12 | 개시 | Oppenheimer | Outperform |
게인 테라퓨틱스 주식(GANX)의 최신 뉴스
Critical Contrast: Gain Therapeutics (NASDAQ:GANX) and Ionis Pharmaceuticals (NASDAQ:IONS) - Defense World
Gain Therapeutics, Inc Advances Parkinson's Treatment to Phase 2 - TradingView
Treasury Yields: What hedge funds are buying Gain Therapeutics IncMarket Growth Report & Long-Term Safe Return Strategies - baoquankhu1.vn
Smart Money: Is Gain Therapeutics Inc part of any major index2025 Buyback Activity & Risk Controlled Daily Plans - baoquankhu1.vn
Is Pediatrix Medical Group Inc. stock undervalued right nowJuly 2025 Breakouts & Technical Confirmation Alerts - baoquankhu1.vn
Published on: 2026-01-31 20:42:39 - baoquankhu1.vn
Wall Street Recap: Can Gain Therapeutics Inc outperform in the next rallyTrade Performance Summary & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
5 Investigational Therapies That Could Change the Parkinson’s Landscape - BioSpace
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - Yahoo Finance
Bond Watch: Will Atlantica Sustainable Infrastructure plc stock benefit from M AMarket Growth Review & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
Aug Final Week: Should I average down on Gain Therapeutics Inc stockNew Guidance & Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Gain Therapeutics Inc. stock attract ESG capital inflowsVolatility Adjusted Trading & Free Stay Informed With Forecasts - Bollywood Helpline
Short Interest in Gain Therapeutics, Inc. (NASDAQ:GANX) Rises By 28.6% - MarketBeat
Aug PreEarnings: Can Gain Therapeutics Inc continue delivering strong returnsJuly 2025 Action & Low Volatility Stock Recommendations - baoquankhu1.vn
Exit Recap: Is Gain Therapeutics Inc attractive for institutional investors2025 Breakouts & Breakdowns & Weekly Watchlist of Top Performers - baoquankhu1.vn
Wall Street Recap: Is Gain Therapeutics Inc trading at a discountWeekly Earnings Recap & Consistent Profit Trading Strategies - baoquankhu1.vn
Pullback Watch: What is Gain Therapeutics Incs 5 year growth outlookTrade Volume Summary & AI Forecast for Swing Trade Picks - baoquankhu1.vn
Movement Recap: Can Gain Therapeutics Inc outperform in the next rallyJuly 2025 Spike Watch & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Fed Impact: Whats the beta of Gain Therapeutics Inc stockMarket Activity Recap & Fast Entry and Exit Trade Plans - baoquankhu1.vn
EPS Watch: Whats the beta of Gain Therapeutics Inc stock2025 EndofYear Setup & Short-Term High Return Strategies - baoquankhu1.vn
Aug Intraday: What is Gain Therapeutics Incs TAM Total Addressable MarketJuly 2025 Breakouts & Daily Profit Focused Stock Screening - baoquankhu1.vn
Why Gain Therapeutics Inc. stock could see breakout soonQuarterly Risk Review & Free Technical Pattern Based Buy Signals - Улправда
Gain Therapeutics Shares Early Phase 1b Data: GT-02287 Shows UPDRS Gains, Key PD Biomarker Drop - Defense World
Reviewing Aldeyra Therapeutics (NASDAQ:ALDX) & Gain Therapeutics (NASDAQ:GANX) - Defense World
How Ideal Power Inc. (5ILA) stock gains from tech spendingJuly 2025 Trade Ideas & Risk Controlled Swing Alerts - Улправда
Will Stoke Therapeutics Inc. stock gain from strong economyJuly 2025 Trends & Verified Short-Term Trading Plans - Улправда
Is Zentalis Pharmaceuticals Inc. stock ready for breakoutGap Up & Low Risk Profit Maximizing Plans - Улправда
Is Gain Therapeutics Inc. stock supported by strong fundamentalsJuly 2025 Momentum & Low Risk Growth Stock Ideas - Улправда
Why Gain Therapeutics Inc. stock attracts high net worth investorsDollar Strength & Risk Controlled Daily Plans - Улправда
Published on: 2026-01-09 02:02:08 - Улправда
Stock Recap: Why Gain Therapeutics Inc. stock attracts high net worth investorsEarnings Overview Summary & Verified Momentum Stock Watchlist - Улправда
Can Gain Therapeutics Inc. stock reach $100 price target2025 Earnings Surprises & Daily Profit Maximizing Tips - Улправда
Gain Therapeutics provides additional data from Phase 1b study of GT-02287 - MSN
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker By Investing.com - Investing.com Nigeria
Gain Therapeutics, Inc. to Participate in Key Events During 44th Annual J.P. Morgan Healthcare Conference Week - Quiver Quantitative
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week - The Manila Times
Biotech firm Gain Therapeutics lines up three events in San Francisco - Stock Titan
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
GANX: GT-02287 reduced GluSph by 81% and improved motor scores in Parkinson's disease patients - TradingView — Track All Markets
Gain Therapeutics reports 81% reduction in Parkinson’s biomarker - Investing.com
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287 - The Manila Times
Why GH Research Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket - Benzinga
Gain Therapeutics, Inc. (NASDAQ:GANX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update - MarketBeat
Research Analysts’ Weekly Ratings Changes for Gain Therapeutics (GANX) - Defense World
GT-02287 boosts enzyme activity in Parkinson’s brain: Trial data - Parkinson's News Today
Gain Therapeutics (GANX) Upgraded to Buy: Here's Why - Yahoo Finance
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data - Investing.com Canada
Roth/MKM raises Gain Therapeutics stock price target to $10 on positive trial data By Investing.com - Investing.com South Africa
게인 테라퓨틱스 (GANX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.23%
1.25%
자본화:
|
볼륨(24시간):